Last €46.67 EUR
Change Today -0.335 / -0.71%
Volume 200.0
MYL On Other Exchanges
As of 8:21 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/27/14 - €47.35
52 Week Low
12/12/13 - €29.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

Pfizer May Acquire Mylan

Mylan, Inc. (NasdaqGS:MYL) is now the most likely takeover target of Pfizer Inc. (NYSE:PFE), says Jefferies. The firm thinks Pfizer management is highly motivated to merge with, invert into or acquire a foreign company. Pfizer may pay 25% premium for Mylan and have the deal be highly accretive.

Johnson & Johnson Provides Update on Claim Alleging Defects in Fentanyl Patch Caused Patient's Death

The U.S. District Court for the Northern District of Oklahoma held the applicable statute of limitations barred an estate's claims against drug manufacturers stemming from the death of a patient due to defects in the manufacturers' fentanyl patch. Rose Ballard and Alana Newton, individually and as co-personal representatives of the estate of Jimmy Ballard, alleged Jimmy Ballard died on Nov. 3, 2005, due to defects in a fentanyl patch. The patch was manufactured, sold, distributed and placed in the stream of commerce by Johnson & Johnson, a/k/a Johnson & Johnson Inc., a/k/a Johnson & Johnson Co., Janssen Pharmaceutical Productions L.P., ALZA Corp., Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan). A fentanyl patch was found on the body at the time of death. Rose and Newton brought an action against Johnson & Johnson, Janssen, ALZA and/or Mylan asserting claims for strict liability, negligence, fraud, wrongful death and breach of warranty. Mylan moved to dismiss alleging the claims were barred by applicable statute of limitations. The district court granted Mylan's motion. The plaintiffs' claims for strict liability, negligence, fraud and wrongful death were subject to two-year statutes of limitation. Mylan's statute of limitations defense was established on the face of the April 25, 2014, petition, which alleged decedent was found dead in his home on Nov. 3, 2005, a fentanyl patch was found on his body, and the medical examiner determined the cause of death was 'toxic effects of fentanyl'. Therefore, the plaintiffs' claims for strict liability, negligence, fraud and wrongful death were time-barred. The district court noted the plaintiffs' claim for breach of warranty was subject to a five-year statute of limitations, and the statute of limitations for breach of warranty accrued upon 'delivery' of the goods, regardless of the aggrieved party's lack of knowledge of the breach. The petition alleged decedent filled the prescription for the fentanyl patch on Nov. 1, 2005. Therefore, the statute of limitations on the plaintiffs' breach of warranty claim ran on Nov. 1, 2010. Accordingly, the breach of warranty claim was time barred.

Mylan Inc. Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to Epipen(R) (Epinephrine) Auto-Injectors

Mylan Inc. announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen(R) (epinephrine) and EpiPen Jr(R) (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions. EpiPen(R) locations will roll out at Disney parks and on cruise ships beginning in late 2014. In addition to emergency medical services (EMS), nurses trained to administer EpiPen Auto-Injectors are available during First Aid station operating hours to assist guests experiencing a severe allergic reaction. To help guests identify EpiPen locations, Disney's guide maps will now include an EpiPen Auto-Injector symbol and new signage at First Aid stations. Anaphylaxis is unpredictable, and can progress quickly and without warning. Clinical guidelines state that epinephrine is the first-line treatment when anaphylaxis occurs, making access critical. For those with a known risk, it is important to be prepared with an anaphylaxis action plan that includes 1) avoiding known allergens, 2) recognizing the signs and symptoms of anaphylaxis, 3) having immediate access to two epinephrine auto-injectors, such as EpiPen Auto-Injector, and 4) seeking immediate emergency medical care should anaphylaxis occur.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:GR €46.67 EUR -0.335

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $69.99 USD +0.39
Perrigo Co PLC $159.22 USD +2.75
UCB SA €62.54 EUR +0.18
WW Grainger Inc $247.16 USD -2.08
WESCO International Inc $85.14 USD -0.52
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 25.3x
Price/Sales 2.9x
Price/Book 6.5x
Price/Cash Flow 23.8x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at